Trial Profile
Abatacept Treatment in Polymyositis and Dermatomyositis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Dermatomyositis; Polymyositis
- Focus Therapeutic Use
- Acronyms ARTEMIS
- 09 Oct 2017 Results published in the Annals of the Rheumatic Diseases Journal.
- 27 Jul 2015 New trial record
- 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.